tiprankstipranks
IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
Germany Market
6IRA
IRLAB Therapeutics AB Class A
RESEARCH TOOLSreports

IRLAB Therapeutics AB Class A (6IRA) Income Statement

1 Followers

IRLAB Therapeutics AB Class A Income Statement

Last quarter (Q4 2025), IRLAB Therapeutics AB Class A's total revenue was kr14.72M, a decrease of -65.61% from the same quarter last year. In Q4, IRLAB Therapeutics AB Class A's net income was kr-23.49M. See IRLAB Therapeutics AB Class A’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
kr 57.46Mkr 94.63Mkr 5.68Mkr 61.14Mkr 207.78M
Gross Profit
kr -92.35Mkr -92.42Mkr -122.73Mkr -111.23Mkr 168.69M
Operating Expenses
kr 0.00kr 33.45Mkr 58.03Mkr 174.25Mkr 116.11M
Depreciation and Amortization
kr 4.32Mkr 4.58Mkr 4.32Mkr 3.98Mkr 3.21M
EBITDA
kr -88.03Mkr -68.07Mkr -173.32Mkr -109.13Mkr 55.79M
Operating Income
kr -92.35Mkr -75.11Mkr -180.76Mkr -113.11Mkr 52.58M
Other Income/Expenses
kr -17.66Mkr -8.02Mkr 2.93Mkr -296.00Kkr -795.00K
Pretax Income
kr -110.01Mkr -83.13Mkr -177.84Mkr -113.41Mkr 51.78M
Net Income
kr -110.01Mkr -83.13Mkr -177.84Mkr -114.20Mkr 51.78M
Per Share Metrics
Basic EPS
kr -1.64kr -1.60kr -3.43kr -2.20kr 1.00
Diluted EPS
kr -1.64kr -1.60kr -3.43kr -2.20kr 1.00
Weighted Average Shares Outstanding
 67.00M 51.87M 51.87M 51.83M 51.75M
Weighted Average Shares Outstanding (Diluted)
 67.00M 51.87M 51.87M 51.83M 51.75M
Currency in SEK

IRLAB Therapeutics AB Class A Earnings and Revenue History